Breast cancer is a multifactorial disease that develops as a result of interactions among genetic, environmental, and hormonal factors. Multiple genetic derangements are believed to be involved in the pathogenesis of breast cancer, including the inactivation of tumor suppressor genes and/or the disregulation of proto-oncogenes. Age, hormones, and environmental factors further influence these genetic derangements. Spontaneous and chemically induced animal models of breast cancer have been limited in their usefulness. The advent of targeted gene mutations has allowed for a more specifi cexploration of the pathogenesis of breast cancer by creating mouse models that mimic single or multiple gene alterations found in human mammary tumors. The genes targeted in these models include mouse mammary tumor integration sites and genes that encode for growth regulators, signal transduction proteins, cell cycle proteins, and cell matrix proteinases. In this review, I summarize tumor morphology and the relevance of each model to the pathogenesis and progression of human breast cancer. These models have great potential for elucidating the multistep process of mammary gland carcinogenesis and for contributing to the identification of novel therapeutic targets.
Ackler S., Ahmad S., Tobias C., Johnson MD, Glazer RI (2000). The development of mammary hyperplasia in MMTV-AKT1 transgenic mice. Proc Am Assoc Cancer Res41: 714 (abstract).
2.
Adjei AA (2000). Signal transduction pathway target for anticancer drug discovery. Curr Pharm Design6: 361—378.
3.
Amundadottir LT, Merlino G., Dickson RB (1996). Transgenic mouse models of breast cancer. Breast Cancer Res Treat39: 119— 135.
4.
Andres AC, Schönenberger CA, Groner B., Henninghausen L., LeMeur M., Gerlinger P. (1987). Ha-ras oncogene expression directed by a milk protein gene promoter: Tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci USA84: 1299—1303.
5.
Asch BB (1996). Tumor viruses and endogenous retrotransposons in mammary tumorigenesis. J Mammary Gland Biol Neoplasia1: 49—60.
6.
Bartek J., Lukas J., Bartkova J. (1999). Perspective: Defects in cell cycle control and cancer. J Pathol187: 95—99.
7.
Bates P., Fisher R., Ward A., Richardson L., Hill DJ, Graham CF (1995). Mammary cancer in transgenic mice expressing insulin-like growth factor-II (IGF-II). Br J Cancer72: 1189—1193.
8.
Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ (2000). Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene19: 1114—1122.
9.
Berg JW (1984). Clinical implications of risk factors for breast cancer. Cancer53: 589—591.
10.
Bergstein I. , Brown AMC (1999). Wnt genes and breast cancer . In: Molecular Genetics, Pathogenesis, and Therapeutics, Bowcock AM (ed). Humana Press , Totowa, New Jersey, pp 181—198.
11.
Bièche I., Laurendau I., Tozlu S., Olivi M., Lidereau R., Vidaud M. (1999). Quantitation of myc gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res59: 2759 — 2765.
12.
Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS (1999). A mouse mammary tumor virus-wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-α . Cancer Res59: 1869—1876.
13.
Bortner DM, Rosenberg MP (1997). Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol17: 453—459.
14.
Bottazzi ME , Assoian RK (1997). The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent kinase inhibitors. Trends Cell Biol7: 348—352.
15.
Bouchard L. , Lamarre L., Tremblay PJ, Jolicoeur P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell57: 931—936.
16.
Callahan R. (1996). MMTV-induced mutations in mouse mammary tumors: Their potential relevance to human breast cancer . Breast Cancer Res Treat39: 33—44.
17.
Callahan R. , Smith GH (2000). MMTV-induced mammary tumorigenesis: Gene discovery, progression to malignancy and cellular pathways . Oncogene19: 992—1001.
18.
Cardiff RD, Gumerlock PH, Soong MM, Dandekar S., Barry PA, Young LJ, Meyers FJ (1988). c-H-ras-1 expression in 7,12-dimethyl benzanthracene—induced Balb/c mouse mammary hyperplasia and their tumors. Oncogene3: 205—213.
19.
Cardiff RD, Muller WJ (1993). Transgenic mouse models of mammary tumorigenesis . In: The Molecular Pathology of Cancer, Lemoine NR, Wright NA (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 97—113.
20.
Cardiff RD, Wellings SR (1999). The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia4: 105—122.
21.
Cardiff RD, Anver MR, Gusterson BA, Hennighausen L., Jensen RA, Merino MJ, Rehm S., Russo J., Tavassoli FA, Wakefield LM, Ward JM, Green JE (2000). The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting . Oncogene19: 968—988.
22.
Couch FJ, Deshano ML, Blackwood MA, Calzone K., Stopfer J., Campeau L., Ganguly A., Rerbeck T., Weber BL (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med336: 1409—1415.
23.
Crook T., Brooks L., Crossland S., Osin P., Barker KT, Waller J., Philp E., Smith PD, Yullug I., Peto J., Parker G., Allday MJ, Crompton MR, Gusterson B. (1998). p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1 and BRCA2 associated breast tumours. Oncogene17: 1681—1689.
24.
Crop CS (1995). Mutations in breast cancer. Cancer Lett90: 51— 56.
25.
Dale TC (1998). Signal transduction by the Wnt family of ligands . Biochem J329: 209—223.
26.
Dankort DL, Muller WJ (2000). Signal transduction in mammary tumorigenesis: A transgenic perspective. Oncogene19: 1038— 1044.
27.
Davies BR, Platt-Higgins AM, Schmidt G., Rudland PS (1999). Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFα transgenic rats. Am J Pathol155: 303—314.
28.
Dawe CJ, Freund R., Mandel G., Ballmer-Hofer K., Talmage DA, Benjamin TA (1987). Variations in polyoma virus genotype in relation to tumor induction in mice. Am J Pathol127: 243—261.
29.
deVries JE (1996). p21ras in carcinogenesis. Pathol Res Pract192: 658—661.
30.
Dickson C., Creer A., Fantl V. (2000). Mammary gland oncogenes as indicators of pathways important in mammary gland development. Oncogene19: 1097—1101.
31.
Doetschman T. (1999). Interpretation of phenotype in genetically engineered mice. Lab Anim Sci49: 137—143.
32.
Donehower LA , Godley L., Aldaz CM, Pyle R., Shi YP, Pinkel D., Gray J., Bradley A., Medina D., Varmus H. (1995). Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability . Genes Dev9: 882—895.
33.
Dow KH (ed) (1996). Contemporary Issues in Breast Cancer. Jones and Bartlett , Sudbury, Massachusetts.
34.
Dunnick JK, Elwell MR, Huff J., Barrett JC (1995). Chemically induced mammary gland cancer in the National Toxicology Program's carcinogenesis bioassay. Carcinogenesis16: 173—179.
35.
Fantl V., Smith R., Brookes S., Dickson C., Peters G. (1993). Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv18: 77—94.
36.
Fioravanti L., Cappelletti V., Coradini D., Miodini P., Borsani G., Daidone MG, Di Fronzo G. (1997). int-2 oncogene amplification and prognosis in node-negative breast carcinoma . Int J Cancer74: 620—624.
37.
Fisher GH, Orsulic S., Holland E., Hively WP, Li Y., Lewis BC, Williams BO, Varmus HE (1999). Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene18: 5253—5260.
38.
Futreal PA, Liu Q., Shattuck-Eidens D., et al (23 coauthors) (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science226: 120—122.
39.
Giani C., Cullen KJ, Campani D., Rasmussen A. (1996). IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat41: 43—50.
40.
Giarré M., Semënov M., Brown AMC (1998). Wnt signaling stabilizes the dual-function protein β-catenin in diverse cell types. Ann NY Acad Sci857: 43—55.
41.
Gibbs JB (2000). Mechanism-based target identification and drug discovery in cancer research. Science287: 1969—1973.
42.
Goldenberg MM (1999). Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther21: 309—318.
43.
Goss PE, Sierra S. (1998). Current perspectives on radiation-induced breast cancer. J Clin Oncol16: 338—347.
44.
Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996). Brca1 defi ciency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet12: 191 — 194.
45.
Green JE, Shibata MA, Yoshidome K., Liu ML, Jorcyk C., Anver MR, Wigginton J., Wiltrout R., Shibata E., Kaczmarczyk S., Wang W., Liu Z., Calvo A., Couldrey C. (2000). The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene19: 1020 — 1027.
46.
Greenblatt MS , Bennett WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis . Cancer Res54: 4855—4878.
47.
Guy CT, Cardiff RD, Muller WJ (1992). Induction of mammary tumors by expression of polyoma middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol12: 954 — 961.
48.
Guy CT, Webster MA, Schaller M., Parsons TJ, Cardiff RD, Muller WJ (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA89: 10578—10582.
49.
Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996). Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology137: 321—330.
50.
Hadsell DL (2000). IGF and insulin action in the mammary gland: Lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia5: 19—30.
51.
Hakem R., de la Pompa JL, Sirard C., et al (12 coauthors) (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell85: 1009—1023.
52.
Horak E., Smith K., Bromley L., Lejune S., Greenall M., Lane D., Harris AL (1991). Mutant p53, EGF receptor and c-erbB2 expression in human breast cancer. Oncogene6: 2277—2284.
53.
Humphreys RC , Hennighausen L. (2000). Transforming growth factor alpha and mouse models of human breast cancer. Oncogene19: 1085—1091.
54.
Jacks T., Remington L., Williams BO, Schmitt EM, Halachmi S., Bronson RT, Weinberg RA (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol4: 1—7.
55.
Jamerson MH , Johnson MD, Dickson RB (2000). Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene19: 1065—1071.
56.
Jäger R., Herzer U., Schenkel J., Weiher H. (1997). Overexpression of bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc—induced tumorigenesis of the mammary gland in transgenic mice. Oncogene15: 1787—1795.
57.
Jerry DJ, Kittrell FS, Kuperwasser C., Laucirica R., Dickinson ES, Bonilla PJ, Butel JS, Medina D. (2000). A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene19: 1052—1058.
58.
Kato K., Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992). Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA89: 6403—6407.
59.
Knudson AG (1993). Antioncogenes and human cancer. Proc Natl Acad Sci USA90: 10914—10921.
60.
Koskinen PJ , Alitalo K. (1993). Pole of myc amplification and overexpression in cell growth differentiation, and death . Semin Cancer Biol4: 3—7.
61.
Krane IM, Leder P. (1996). NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene12: 1781—1788.
62.
Kumar R., Medina D., Sukumar S. (1990). Activation of H-ras oncogenes in preneoplastic mouse mammary tissues. Oncogene5: 1271—1277.
63.
Kwan H., Pacenka V., Tsukamoto A., Parslow TG, Guzman R., Lin TP, Muller WJ, Lee FS, Leder P. (1992). Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during carcinogenesis in doubly transgenic mice. Mol Cell Biol12: 147—154.
64.
Lammie GA, Peters G. (1991). Chromosome 11q13 abnormalities in human cancer cells. Cancer Cells3: 413 — 420.
65.
Lancaster J. , Wooster R., Mangion J., et al (17 coauthors) ( 1996). BRCA2 mutations in primary breast and ovarian cancers . Nat Genet13: 238—240.
66.
Le XF, McWatters A., Wiener J., Wu JY, Mills GB, Bast RC ( 2000). Anti-Her2 antibody and heregulin suppress growth of Her2-overexpressing human breast cancer cells through different mechanism. Clin Cancer Res6: 260—270.
67.
Lee EYHP (1995). Tumor suppressor genes and their alterations in breast cancer. Semin Cancer Biol6: 119 — 125.
68.
Levi F., Pasche C., Lucchini F., La Vecchia C. (1996). Alcohol and breast cancer in the Swiss Canton of Vaud. Eur J Cancer32A: 2108—2113.
69.
Li B., Rosen J., McMenamin-Balano J., Muller WJ, Perkins AS (1997). neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol17: 3155—3163.
70.
Li M., Lewis B., Capuco AV, Laucircia R., Furth PA (2000). WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene19: 1010—1019.
71.
Li Y., Hively WP, Varmus HE (2000). Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene19: 1002—1009.
72.
Liu CY, Flesken-Nikitin A., Li S., Zeng Y., Lee WH (1996). Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early post-implantation development. Genes Dev10: 1835—1843.
73.
Lubin F., Wax Y., Modan B. (1986). Role of fat, animal protein, and dietary fiber in breast cancer etiology: A case-control study. J Natl Cancer Inst77: 605—612.
74.
Ludwig T., Chapman DL, Papaioannou VE, Efstratiadis A. (1997). Targeted mutations of breast cancer susceptibility genes homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/ p53, and Brca2/p53 nullizygous embryos. Genes Dev11: 1226 — 1241.
75.
Lundgren K. , Montes de Oca Luna R., Mcneill YB, Emerick EP, Spencer B., Barfield CR, Lozano G., Rosenberg MP, Finlay CA (1997). Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary development independent of p53. Genes Dev11: 714 — 725.
76.
Macleod KF, Jacks T. (1999). Insights into cancer from transgenic mouse models . J Pathol187: 43—60.
77.
Malkin D., Li FP, Strong LC, Fraumeni JF, Nelsom CE, Kim DH, Kassel J., Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science250: 1233—1238.
78.
Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA (1998). BRCA1 mutations and breast cancer in the general population. J Am Med Assoc279: 922—929.
79.
Matsui Y., Halteer SA, Hogan BL, Coffey RJ (1990). Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell61: 1147—1155.
80.
McGregor DH , Land CE, Choi K., Tokuooka S., Liu PI, Wakabayashi T., Beebe GW (1977). Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950—69. J Natl Cancer Inst59: 799—811.
81.
McKenzie K., Sukumar S. (1996). Molecular genetics of human breast cancer. In: Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences, Huff J, Boyd J, Barrett JC (eds). Wiley-Liss, New York, pp 183—209.
82.
Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ, Risch HA, Prestom DL (1989). Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis . N Engl J Med321: 1285—1289.
83.
Muller WJ, Lee FS, Dickson C., Peters G., Pattengale PK, Leder P. (1990). The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J9: 907—913.
84.
Nass SJ, Dickson RB (1997). Defining a role for c-Myc in breast tumorigenesis . Breast Cancer Res Treat44: 1—22.
85.
Nelson AR, Fingleton B., Rothenburg ML, Matrisian LM (2000). Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol18: 1135—1149.
86.
Newman B., Mu H., Butler LM, Millikan RC, Moorman PG, King M. ( 1998). Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. J Am Med Assoc279: 915—921.
87.
Nielsen LL, Discafani CM, Gurnani M., Tyler RD (1991). Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res51: 3762— 3767.
88.
Nusse R. (1991). Insertional mutagenesis in mouse mammary tumorigenesis . Curr Top Microbiol Immunol171: 43—65.
89.
Paik S. (1992). Expression of IGF-I and IGF-II in breast tissue . Breast Cancer Res Treat22: 31—38.
90.
Papkoff J., Aikawa M. (1998). Wnt-1 and HGF regulate GSK3β activity and β-catenin signaling in mammary epithelial cells. Biochem Biophys Res Commun247: 851—858.
91.
Peyrat JP, Bonneterre J., Hecquet B., Vennin P., Louchez MM, Fournier C., Lefebvre J., Demaille A. (1993). Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer29A: 492 — 497.
Pusztal L. (1993). Growth factors: Regulation of normal and neoplastic growth. J Pathol169:191—201.
94.
Railo MJ, von Smitten K., Pekonen F. (1994). The prognostic value of insulin-like growth factor-I in breast cancer patients: Results of a follow-up study on 126 patients. Eur J Cancer30A: 307—311.
95.
Rao GN, Ney E., Herbert RA (1997). Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue. Breast Cancer Res Treat45: 149—158.
96.
Reese DM, Slamon DJ (1997). HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells15: 1—8.
97.
Rose-Hellekant TA, Sandgren EP (2000). Transforming growth factor alpha— and c-myc—induced mammary carcinogenesis in transgenic mice. Oncogene19: 1092—1096.
98.
Rose DP (1997). Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med216: 224—233.
99.
Rosen JM, Humphreys R., Krnacik S., Juo P., Raught B. (1994). The regulation of mammary gland development by hormones, growth factors, and oncogenes. Prog Clin Biol Res387: 95—111.
100.
Rowse GJ, Ritland SR, Gendler SJ (1998). Genetic modulation of neu proto-oncogene—induced mammary tumorigenesis. Cancer Res58: 2675—2679.
101.
Ruan W., Kleinberg DL (1999). Insulin-like growth factor-I is essential for terminal end bud formation and ductal morphogenesis during mammary development . Endocrinology140: 5075—5081.
102.
Rudolph-Owen LA, Chan R., Muller WJ, Matrisian LM (1998). The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis . Cancer Research58: 5500—5506.
103.
Rudolph-Owen LA, Matrisian LM (1998). Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. Journal of Mammary Gland Biology and Neoplasia3: 177—189.
104.
Russo J., Gusterson B., Rogers AE, Russo IH, Wellings SR, van Zweiten MJ (1990). Comparative study of human and rat mammary tumorigenesis . Laboratory Investigation62: 244—278.
105.
Russo J., Russo IH, Rogers AE, Zwieten MJV, Gusterson B. (1990). Tumours of the mammary gland. In: Pathology of Tumours in Laboratory Animals, Turusov V. and Mohr U. (eds). IARC Scientific Publications, Lyon, France, pp. 47—78.
106.
Salomon DS (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. CritRev Hematol Oncol19: 183—191.
107.
Sandgren E. , Luetteke N., Palmiter R., Brinster R., Lee DC (1990). Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell61: 1121—1135.
108.
Sandgren EP , Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC (1995). Inhibition of mammary gland involution is associated with transforming growth factor not c-myc induced tumorigenesis in transgenic mice. Cancer Research55: 3915—3927.
109.
Sass B., Dunn TB ( 1979). Classification of mouse mammary tumours in Dunn's miscellaneous group including recently reported types. J Natl Cancer Inst62: 1287—1293.
110.
Sauer B. (1998). Inducible gene targeting in mice using the Cre/ lox system. Methods14: 381—392.
111.
Schafer WR , Kim R., Sterne R., Thorner J., Kim SH, Rine J. (1989). Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science245: 379—385.
112.
Schönenberger CA, Andres AC, Groner B., van der Valk M., LeMeur M., Gerlinger P. (1988). Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein transcription. EMBO J7: 169—175.
113.
Schulze-Garg C., Löhler J., Gocht A., Deppert W. (2000). A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene19: 1028—1037.
114.
Shimizu H. , Julius MA, Giarré M., Zheng Z., Brown AMC, Kitajewski J. (1997). Transformation by Wnt family proteins correlates with regulation of β-catenin . Cell Growth Differ8: 1349—1358.
115.
Sinn E., Muller WJ, Pattengale PK, Tepler I., Wallace R., Leder P. (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell54: 105—115.
116.
Smith CA, Pollice AA, Gu LP, Brown KA, Singh SG, Janocko LE, Johnson R., Julian T., Hyams D., Wolmark N., Sweeney L., Silverman JF, Shackney SE (2000). Correlations among p53, Her/ neu, and ras overexpression and aneuploidy by multiparameter fl ow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas . Clin Cancer Res6: 112—126.
117.
Squartini F. , Pingitore R. (1994). Tumours of the mammary gland. In: Pathology of Tumours in Laboratory Animals, Turusov V, Mohr U (eds). IARC Scientific Publications, Lyon, France, pp 47— 100.
118.
Sternlicht MD, Bissell MJ, Werb Z. (2000). The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene19: 1102—1113.
119.
Sternlicht MD, Lochter A., Sympson CJ, Huey B., Rougier JP, Gray JW, Pinkel D., Bissell MJ, Werb Z. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis . Cell: 137—146.
120.
Stewart TA , Pattengale PK, Leder P. (1984). Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MMTV/myc fusion genes. Cell38: 627—637.
121.
Stratton M. (1996). Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet5: 1515—1519.
122.
Surmacz E. (2000). Function of the IGF-1 receptor in breast cancer. J Mammary Gland Biol Neoplasia5: 95—105.
123.
Teng DHF , Bogden R., Mitchell JT, et al (15 coauthors) (1996). Low incidence of BRCA mutations in breast carcinoma and other cancers. Nat Genet13: 241—244.
124.
Thomas DB (1984). Do hormones cause breast cancer?Cancer53: 595—604.
125.
Tsukamoto AS, Grosschedl R., Guzman RC, Parslow T., Varmus HE (1988). Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell55: 619—625.
126.
Vomachka A. , Pratt SL, Lockefeer J., Horseman ND (2000). Prolactin gene-disruption arrests mammary gland development and retards T-antigen—induced tumor growth. Oncogene19: 1077— 1084.
127.
Vos CBJ , Ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJ (1999). Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol187: 279—284.
128.
Walker RA, Varley JM (1993). The molecular pathology of human breast cancer . In: The Molecular Pathology of Cancer, Lemoine NR, Wright NA (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 31—57.
129.
Wang TC, Cardiff RD, Zuckerberg L., Lees E., Arnold A., Schmidt EV (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature369: 669—671.
130.
Watson PH, Pon RT, Shiu RP ( 1991). Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res51: 3996 — 4000.
131.
Webster M., Cardiff RD, Muller WJ (1995). Induction of mammary epithelial hyperplasia and mammary tumors in transgenic mice expressing a murine mammary tumor virus activated c-src fusion gene. Proc Natl Acad Sci USA92: 78849—7853.
132.
Welsch CW, Brown CK, Goodrich-Smith M., Van J., Denenberg B., Anderson TM, Brooks CL (1979). Inhibition of mammary tumorigenesis in carcinogen-treated Lewis rats by suppression of prolactin secretion. J Natl Cancer Inst63: 1211—1214.
133.
Willsher PC , Beaver J., Pinder S., Bell JA, Ellis IO, Blamey RW, Robertson JFR (1996). Prognostic significance of serum c-erbB-2 protein in breast cancer patients . Breast Cancer Res Treat40: 251—255.
134.
Witty JP, Wright JH, Matrisian LM (1995). Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol Cell Biol6: 1287—1303.
135.
Wood TL, Richert MM, Stull MA, Allar MA (2000). The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. JMammary Gland Biol Neoplasia5: 31—42.
136.
Xu X., Wagner K., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., Deng C. ( 1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet22: 37—43.
137.
Yee D. , Lee AV (2000). Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia5: 107—115.
